A Study of IBI362 in Participants With Obesity or Overweight

NCT05607680 on ClinicalTrials.gov · last registry update 2024-11-12

Finished 21 August 2023, after enrolling 610 people. Primary outcome, as filed: Percent Change from Baseline in Body Weight. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.

Status: COMPLETED
Phase: P3
Drug: mazdutide
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Sponsor type: Industry
Enrollment: 610
Started: 2022-11-14
Primary completion: 2023-08-21 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change from Baseline in Body Weight

Conditions studied

Obesity Or Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.